Investigators reported a favorable safety profile following a single 2×10^7 CFU booster of the live-attenuated cholera vaccine PanChol. Nine of 20 participants (45%) experienced at least one solicited adverse event; most solicited events—13 of 14—were graded mild and resolved quickly. The most common solicited symptom was nausea, occurring in four participants (20%), and all cases were mild. Unsolicited adverse events were generally mild as well; one grade 3 unsolicited event occurred but was judged unrelated to vaccination by the study team. Two unsolicited events (a transient gassy sensation and brief heartburn) were assessed as vaccine-related and both resolved the same day they occurred. The trial reported no serious adverse events attributable to the booster. These safety observations apply to the studied adult cohort only; the source did not report safety data for children or for alternative dosing regimens beyond the documented booster dose.
The study team measured serum vibriocidal titers to both Inaba and Ogawa serotypes before and after the booster to quantify humoral durability and boosting. On the day of boosting, most participants retained elevated titers compared with their pre-primary baseline: 17 of 20 (85%) for Inaba and 14 of 20 (70%) for Ogawa. After administration of the 2×10^7 CFU booster, 15 of 20 participants (75%) achieved seroconversion—defined in the protocol as a fourfold rise in vibriocidal titer—from their baseline to both serotypes. The cohort therefore showed both durable antibody signal months to years after the initial dose (the source reports prior dosing occurred 322–1111 days earlier) and a robust anamnestic response in most boost recipients.
The manuscript does not report additional serologic correlates beyond vibriocidal titers, nor does it provide granular per-participant titer trajectories or statistical significance testing in the text excerpt available. The study team limited immunogenicity endpoints to vibriocidal magnitude, seroconversion proportion, and temporal comparisons relative to the initial immunization.
The investigators used quantitative and qualitative stool cultures to assess PanChol shedding as a surrogate for intestinal colonization and mucosal immunity. After the booster, 17 of 20 participants (85%) had no or only self-limited vaccine shedding. By contrast, only 10% of participants had that low level of shedding after the first PanChol dose. The study team interpreted the marked reduction in fecal abundance of vaccine organisms following the second dose—relative to the initial exposure—as evidence that the primary dose induced durable mucosal defenses sufficient to limit intestinal colonization on re-exposure.
Stool culture outcomes were reported as comparative proportions in the source. The manuscript excerpt did not include quantitative colony counts for each time point nor detailed kinetics of shedding (for example, days post-vaccination when cultures turned negative), so those specifics cannot be summarized here because they were not reported.
This was an open-label phase 1a booster trial conducted at Brigham and Women’s Hospital. Eligible adults were aged 18–55, healthy, without prior cholera or relevant gastrointestinal disorders, and had previously received a single PanChol dose that ranged from 10^5 to 10^10 colony-forming units (CFU) between 322 and 1,111 days before enrollment. The booster dose administered to all participants in this follow-up was 2×10^7 CFU. Twenty participants were enrolled between Aug 25, 2025, and Feb 20, 2026. Eleven participants (55%) were male and the median age reported was 43.6 years (IQR 30.2–49.5). Ten participants (50%) were White and 17 (85%) identified as not Hispanic or Latino.
Primary outcome measures focused on safety (solicited, unsolicited, and serious adverse events) after the second dose. Secondary endpoints included the magnitude of pre- and post-boost vibriocidal titers to Inaba and Ogawa, seroconversion rates defined by a fourfold rise from baseline, and stool shedding by culture. The trial is registered on ClinicalTrials.gov under NCT05657782 and is reported as complete in the source document.
The authors state that these observations support continued clinical development of PanChol, but they also leave specific unanswered questions documented in the manuscript. The cohort was small (20 adults) and limited to healthy adults; the source did not present pediatric data or effectiveness against clinical cholera disease. The excerpt does not report detailed quantitative shedding kinetics, per-participant titer tables, or formal statistical tests for some comparisons; those data were not included in the provided text. Investigators noted reduced fecal shedding after the booster compared with the initial dose and inferred durable mucosal immunity from that finding, yet direct challenge or field efficacy data were not part of this phase 1 booster study.
Funding was provided by the Wellcome Trust and other listed sources. One author disclosed inventorship on a PanChol-related patent; additional competing interests were declared as detailed in the source. The trial registration identifier (NCT05657782) is provided. The study team recommends further clinical development; the source itself does not specify exact regulatory milestones or timelines, nor does it report plans for larger efficacy trials within the excerpt available. Those next steps remain to be defined in subsequent protocols and regulatory submissions.